title: Study of the absorption of cefcapene pivoxil in patients with infectious disease and soft stool or diarrhea.
abstract: Cefcapene pivoxil hydrochloride (CFPN-PI), an ester cephem antibiotic, was orally given at a dose of 100 mg three times daily in patients with infection and soft stool or diarrhea, and its absorption was determined using the recovery ratio of 12-h urine pooled after the initial administration as an index. The primary endpoint, the recovery ratio of 12-h urine pooled after oral administration, could be evaluated in six of the eight patients finally gathered, and the mean value was 30.1 +/- 5.8%, which was not considered to differ from the mean value of 34.4 +/- 5.5% obtained in six healthy adult volunteers in the previous phase I study. Clinical efficacy in the eight patients was rated as very effective, effective, and ineffective in two, five, and one patients, respectively, with an effective ratio of 87.5% (7/8). Neither adverse drug reactions nor abnormal laboratory data were observed in any patient. These results indicate that CFPN-PI, at the routine oral dose, does not cause any problems in terms of absorption, efficacy, and safety when it is used in patients with infection and soft stool or diarrhea.
authors.affiliation: Second Department of Surgery, Wakayama Medical University, 811-1 Kimiidera, Wakayama 641-8510, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Tanimura
authors.forename: Kazuhisa
authors.initials: K
authors.lastname: Uchiyama
authors.forename: Hironobu
authors.initials: H
authors.lastname: Onishi
authors.forename: Shigeru
authors.initials: S
authors.lastname: Akimoto
authors.forename: Minoru
authors.initials: M
authors.lastname: Ochiai
authors.forename: Tadashi
authors.initials: T
authors.lastname: Kontani
authors.forename: Yasuhito
authors.initials: Y
authors.lastname: Kobayasi
authors.forename: Kiyofumi
authors.initials: K
authors.lastname: Johata
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Hotta
authors.forename: Masaki
authors.initials: M
authors.lastname: Sahara
authors.forename: Kazuhito
authors.initials: K
authors.lastname: Masaki
authors.forename: Kohei
authors.initials: K
authors.lastname: Noguchi
authors.forename: Shinji
authors.initials: S
authors.lastname: Iwakura
mesh_terms: D000042:Absorption; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002511:Cephalosporins / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D003141:Communicable Diseases / Q000188:drug therapy* / Q000382:microbiology; D003967:Diarrhea / Q000188:drug therapy*; D005243:Feces / Q000737:chemistry / Q000382:microbiology; D005260:Female; D005767:Gastrointestinal Diseases / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014556:Urine / Q000737:chemistry*
chemical_list: D002511:Cephalosporins; C425944:cefcapene pivoxil hydrochloride